Global (United States, European Union and China) Endometriosis Drugs

Endometriosis Drugs Comprehensive Study by Application (Hospitals, Clinics, Research Institutes, Others), Route of Administration (Oral, Nasal Spray, Intrauterine Systems, Parenteral), Therapy Type (Pain Management, Hormonal Therapy), Age Group (Child, Adult, Senior), Drug Class (Gonadotropins Releasing Hormone Agonists, Progestin, Non-Steroidal Anti-Inflammatory Drugs, Oral Contraceptive Pills) Players and Region - Global Market Outlook to 2030

Endometriosis Drugs Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Endometriosis Drugs
Endometriosis is a lifelong condition so it is important to develop a plan to manage it based on the extent of the disease, severity of pain and potential plans for pregnancy. Since it is a chronic disease, it cannot be cured, but there are options for different types of medications to ease endometriosis pain and help you feel better. this is major driving force of the global endometriosis drugs market. Women’s diseases have increased significantly and more and more innovative drugs and treatments are being introduced to ease their suffering. One of the most prevalent diseases is endometriosis and there are about 170 million women across the globe facing it. With this large number of women facing endometriosis, huge developments are taking place in endometriosis treatment by including advanced technologies.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that European and United States Players will contribute the maximum growth to Global Endometriosis Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AbbVie (United States), Astellas Pharma (Japan), AstraZeneca plc (United Kingdom), Debiopharm Group (Switzerland), Evotec AG (Germany), Kissei Pharmaceutical (Japan), Neurocrine Biosciences, Inc. (United States), ObsEva (Switzerland), Pfizer Inc. (United States) and Repros Therapeutics Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Roivant Sciences GmbH (Switzerland), Takeda Pharmaceutical Company Limited (Japan) and ValiRx (United Kingdom).

Segmentation Overview
AMA Research has segmented the market of Global Endometriosis Drugs market by , Application (Hospitals, Clinics, Research Institutes and Others) and Region.



On the basis of geography, the market of Endometriosis Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Endometriosis Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapy Type, the sub-segment i.e. Pain Management will boost the Endometriosis Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Age Group, the sub-segment i.e. Child will boost the Endometriosis Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Gonadotropins Releasing Hormone Agonists will boost the Endometriosis Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
increased Adoption of Oral Contraceptive Pill

Market Growth Drivers:
Increased Awareness about the Disease and Rising Incidents of Endometriosis due to Improved Diagnostics Techniques

Challenges:
Poor Success Rate

Restraints:
Ineffective Drugs Therapies

Opportunities:
Technological Advancement and Development in the Endometriosis Drugs

Market Leaders and their expansionary development strategies
On 26th January 2021, Myovant Sciences and Pfizer Inc. have announced that the Phase 3 SPIRIT long-term extension study of the investigational once-daily relugolix combination therapy in women with endometriosis reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain over one year (52 weeks) with minimal and stable bone mineral density loss.
In August 2022, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a one-pill, once-a-day therapy for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months. The approval is supported by one-year efficacy and safety data, including 24-week data from the Phase 3 SPIRIT 1 and SPIRIT 2 trials, which were published in The Lancet, and the first 28 weeks of an open-label extension study for eligible women who completed either SPIRIT 1 or SPIRIT 2. MYFEMBREE also is approved for heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Myovant and Pfizer will continue to jointly commercialize MYFEMBREE in the U.S. and product is available immediately.


Key Target Audience
Endometriosis Drugs Manufacturers, Research Institutes, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Clinics
  • Research Institutes
  • Others
By Route of Administration
  • Oral
  • Nasal Spray
  • Intrauterine Systems
  • Parenteral

By Therapy Type
  • Pain Management
  • Hormonal Therapy

By Age Group
  • Child
  • Adult
  • Senior

By Drug Class
  • Gonadotropins Releasing Hormone Agonists
  • Progestin
  • Non-Steroidal Anti-Inflammatory Drugs
  • Oral Contraceptive Pills

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Awareness about the Disease
      • 3.2.2. Rising Incidents of Endometriosis due to Improved Diagnostics Techniques
    • 3.3. Market Challenges
      • 3.3.1. Poor Success Rate
    • 3.4. Market Trends
      • 3.4.1. Increased Adoption of Oral Contraceptive Pill
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Endometriosis Drugs, by Application, Route of Administration, Therapy Type, Age Group, Drug Class and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Endometriosis Drugs (Value)
      • 5.2.1. Global Endometriosis Drugs by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Research Institutes
        • 5.2.1.4. Others
      • 5.2.2. Global Endometriosis Drugs by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Nasal Spray
        • 5.2.2.3. Intrauterine Systems
        • 5.2.2.4. Parenteral
      • 5.2.3. Global Endometriosis Drugs by: Therapy Type (Value)
        • 5.2.3.1. Pain Management
        • 5.2.3.2. Hormonal Therapy
      • 5.2.4. Global Endometriosis Drugs by: Age Group (Value)
        • 5.2.4.1. Child
        • 5.2.4.2. Adult
        • 5.2.4.3. Senior
      • 5.2.5. Global Endometriosis Drugs by: Drug Class (Value)
        • 5.2.5.1. Gonadotropins Releasing Hormone Agonists
        • 5.2.5.2. Progestin
        • 5.2.5.3. Non-Steroidal Anti-Inflammatory Drugs
        • 5.2.5.4. Oral Contraceptive Pills
      • 5.2.6. Global Endometriosis Drugs Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Endometriosis Drugs (Volume)
      • 5.3.1. Global Endometriosis Drugs by: Application (Volume)
        • 5.3.1.1. Hospitals
        • 5.3.1.2. Clinics
        • 5.3.1.3. Research Institutes
        • 5.3.1.4. Others
      • 5.3.2. Global Endometriosis Drugs by: Route of Administration (Volume)
        • 5.3.2.1. Oral
        • 5.3.2.2. Nasal Spray
        • 5.3.2.3. Intrauterine Systems
        • 5.3.2.4. Parenteral
      • 5.3.3. Global Endometriosis Drugs by: Therapy Type (Volume)
        • 5.3.3.1. Pain Management
        • 5.3.3.2. Hormonal Therapy
      • 5.3.4. Global Endometriosis Drugs by: Age Group (Volume)
        • 5.3.4.1. Child
        • 5.3.4.2. Adult
        • 5.3.4.3. Senior
      • 5.3.5. Global Endometriosis Drugs by: Drug Class (Volume)
        • 5.3.5.1. Gonadotropins Releasing Hormone Agonists
        • 5.3.5.2. Progestin
        • 5.3.5.3. Non-Steroidal Anti-Inflammatory Drugs
        • 5.3.5.4. Oral Contraceptive Pills
      • 5.3.6. Global Endometriosis Drugs Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Endometriosis Drugs (Price)
  • 6. Endometriosis Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbVie (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Astellas Pharma (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AstraZeneca plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Debiopharm Group (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Evotec AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Kissei Pharmaceutical (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Neurocrine Biosciences, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. ObsEva (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Repros Therapeutics Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Endometriosis Drugs Sale, by Application, Route of Administration, Therapy Type, Age Group, Drug Class and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Endometriosis Drugs (Value)
      • 7.2.1. Global Endometriosis Drugs by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Research Institutes
        • 7.2.1.4. Others
      • 7.2.2. Global Endometriosis Drugs by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Nasal Spray
        • 7.2.2.3. Intrauterine Systems
        • 7.2.2.4. Parenteral
      • 7.2.3. Global Endometriosis Drugs by: Therapy Type (Value)
        • 7.2.3.1. Pain Management
        • 7.2.3.2. Hormonal Therapy
      • 7.2.4. Global Endometriosis Drugs by: Age Group (Value)
        • 7.2.4.1. Child
        • 7.2.4.2. Adult
        • 7.2.4.3. Senior
      • 7.2.5. Global Endometriosis Drugs by: Drug Class (Value)
        • 7.2.5.1. Gonadotropins Releasing Hormone Agonists
        • 7.2.5.2. Progestin
        • 7.2.5.3. Non-Steroidal Anti-Inflammatory Drugs
        • 7.2.5.4. Oral Contraceptive Pills
      • 7.2.6. Global Endometriosis Drugs Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Endometriosis Drugs (Volume)
      • 7.3.1. Global Endometriosis Drugs by: Application (Volume)
        • 7.3.1.1. Hospitals
        • 7.3.1.2. Clinics
        • 7.3.1.3. Research Institutes
        • 7.3.1.4. Others
      • 7.3.2. Global Endometriosis Drugs by: Route of Administration (Volume)
        • 7.3.2.1. Oral
        • 7.3.2.2. Nasal Spray
        • 7.3.2.3. Intrauterine Systems
        • 7.3.2.4. Parenteral
      • 7.3.3. Global Endometriosis Drugs by: Therapy Type (Volume)
        • 7.3.3.1. Pain Management
        • 7.3.3.2. Hormonal Therapy
      • 7.3.4. Global Endometriosis Drugs by: Age Group (Volume)
        • 7.3.4.1. Child
        • 7.3.4.2. Adult
        • 7.3.4.3. Senior
      • 7.3.5. Global Endometriosis Drugs by: Drug Class (Volume)
        • 7.3.5.1. Gonadotropins Releasing Hormone Agonists
        • 7.3.5.2. Progestin
        • 7.3.5.3. Non-Steroidal Anti-Inflammatory Drugs
        • 7.3.5.4. Oral Contraceptive Pills
      • 7.3.6. Global Endometriosis Drugs Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Endometriosis Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Endometriosis Drugs: by Application(USD Million)
  • Table 2. Endometriosis Drugs Hospitals , by Region USD Million (2018-2023)
  • Table 3. Endometriosis Drugs Clinics , by Region USD Million (2018-2023)
  • Table 4. Endometriosis Drugs Research Institutes , by Region USD Million (2018-2023)
  • Table 5. Endometriosis Drugs Others , by Region USD Million (2018-2023)
  • Table 6. Endometriosis Drugs: by Route of Administration(USD Million)
  • Table 7. Endometriosis Drugs Oral , by Region USD Million (2018-2023)
  • Table 8. Endometriosis Drugs Nasal Spray , by Region USD Million (2018-2023)
  • Table 9. Endometriosis Drugs Intrauterine Systems , by Region USD Million (2018-2023)
  • Table 10. Endometriosis Drugs Parenteral , by Region USD Million (2018-2023)
  • Table 11. Endometriosis Drugs: by Therapy Type(USD Million)
  • Table 12. Endometriosis Drugs Pain Management , by Region USD Million (2018-2023)
  • Table 13. Endometriosis Drugs Hormonal Therapy , by Region USD Million (2018-2023)
  • Table 14. Endometriosis Drugs: by Age Group(USD Million)
  • Table 15. Endometriosis Drugs Child , by Region USD Million (2018-2023)
  • Table 16. Endometriosis Drugs Adult , by Region USD Million (2018-2023)
  • Table 17. Endometriosis Drugs Senior , by Region USD Million (2018-2023)
  • Table 18. Endometriosis Drugs: by Drug Class(USD Million)
  • Table 19. Endometriosis Drugs Gonadotropins Releasing Hormone Agonists , by Region USD Million (2018-2023)
  • Table 20. Endometriosis Drugs Progestin , by Region USD Million (2018-2023)
  • Table 21. Endometriosis Drugs Non-Steroidal Anti-Inflammatory Drugs , by Region USD Million (2018-2023)
  • Table 22. Endometriosis Drugs Oral Contraceptive Pills , by Region USD Million (2018-2023)
  • Table 23. South America Endometriosis Drugs, by Country USD Million (2018-2023)
  • Table 24. South America Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 25. South America Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 26. South America Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 27. South America Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 28. South America Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 29. Brazil Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 30. Brazil Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 31. Brazil Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 32. Brazil Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 33. Brazil Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 34. Argentina Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 35. Argentina Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 36. Argentina Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 37. Argentina Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 38. Argentina Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 39. Rest of South America Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 40. Rest of South America Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 41. Rest of South America Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 42. Rest of South America Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 43. Rest of South America Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 44. Asia Pacific Endometriosis Drugs, by Country USD Million (2018-2023)
  • Table 45. Asia Pacific Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 46. Asia Pacific Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 47. Asia Pacific Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 48. Asia Pacific Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 49. Asia Pacific Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 50. China Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 51. China Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 52. China Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 53. China Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 54. China Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 55. Japan Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 56. Japan Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 57. Japan Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 58. Japan Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 59. Japan Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 60. India Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 61. India Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 62. India Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 63. India Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 64. India Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 65. South Korea Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 66. South Korea Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 67. South Korea Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 68. South Korea Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 69. South Korea Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 70. Taiwan Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 71. Taiwan Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 72. Taiwan Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 73. Taiwan Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 74. Taiwan Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 75. Australia Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 76. Australia Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 77. Australia Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 78. Australia Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 79. Australia Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 80. Rest of Asia-Pacific Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 81. Rest of Asia-Pacific Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 82. Rest of Asia-Pacific Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 83. Rest of Asia-Pacific Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 84. Rest of Asia-Pacific Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 85. Europe Endometriosis Drugs, by Country USD Million (2018-2023)
  • Table 86. Europe Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 87. Europe Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 88. Europe Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 89. Europe Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 90. Europe Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 91. Germany Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 92. Germany Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 93. Germany Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 94. Germany Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 95. Germany Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 96. France Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 97. France Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 98. France Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 99. France Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 100. France Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 101. Italy Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 102. Italy Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 103. Italy Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 104. Italy Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 105. Italy Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 106. United Kingdom Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 107. United Kingdom Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 108. United Kingdom Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 109. United Kingdom Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 110. United Kingdom Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 111. Netherlands Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 112. Netherlands Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 113. Netherlands Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 114. Netherlands Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 115. Netherlands Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 116. Rest of Europe Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 117. Rest of Europe Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 118. Rest of Europe Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 119. Rest of Europe Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 120. Rest of Europe Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 121. MEA Endometriosis Drugs, by Country USD Million (2018-2023)
  • Table 122. MEA Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 123. MEA Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 124. MEA Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 125. MEA Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 126. MEA Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 127. Middle East Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 128. Middle East Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 129. Middle East Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 130. Middle East Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 131. Middle East Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 132. Africa Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 133. Africa Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 134. Africa Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 135. Africa Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 136. Africa Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 137. North America Endometriosis Drugs, by Country USD Million (2018-2023)
  • Table 138. North America Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 139. North America Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 140. North America Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 141. North America Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 142. North America Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 143. United States Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 144. United States Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 145. United States Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 146. United States Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 147. United States Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 148. Canada Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 149. Canada Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 150. Canada Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 151. Canada Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 152. Canada Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 153. Mexico Endometriosis Drugs, by Application USD Million (2018-2023)
  • Table 154. Mexico Endometriosis Drugs, by Route of Administration USD Million (2018-2023)
  • Table 155. Mexico Endometriosis Drugs, by Therapy Type USD Million (2018-2023)
  • Table 156. Mexico Endometriosis Drugs, by Age Group USD Million (2018-2023)
  • Table 157. Mexico Endometriosis Drugs, by Drug Class USD Million (2018-2023)
  • Table 158. Endometriosis Drugs Sales: by Application(Kg)
  • Table 159. Endometriosis Drugs Sales Hospitals , by Region Kg (2018-2023)
  • Table 160. Endometriosis Drugs Sales Clinics , by Region Kg (2018-2023)
  • Table 161. Endometriosis Drugs Sales Research Institutes , by Region Kg (2018-2023)
  • Table 162. Endometriosis Drugs Sales Others , by Region Kg (2018-2023)
  • Table 163. Endometriosis Drugs Sales: by Route of Administration(Kg)
  • Table 164. Endometriosis Drugs Sales Oral , by Region Kg (2018-2023)
  • Table 165. Endometriosis Drugs Sales Nasal Spray , by Region Kg (2018-2023)
  • Table 166. Endometriosis Drugs Sales Intrauterine Systems , by Region Kg (2018-2023)
  • Table 167. Endometriosis Drugs Sales Parenteral , by Region Kg (2018-2023)
  • Table 168. Endometriosis Drugs Sales: by Therapy Type(Kg)
  • Table 169. Endometriosis Drugs Sales Pain Management , by Region Kg (2018-2023)
  • Table 170. Endometriosis Drugs Sales Hormonal Therapy , by Region Kg (2018-2023)
  • Table 171. Endometriosis Drugs Sales: by Age Group(Kg)
  • Table 172. Endometriosis Drugs Sales Child , by Region Kg (2018-2023)
  • Table 173. Endometriosis Drugs Sales Adult , by Region Kg (2018-2023)
  • Table 174. Endometriosis Drugs Sales Senior , by Region Kg (2018-2023)
  • Table 175. Endometriosis Drugs Sales: by Drug Class(Kg)
  • Table 176. Endometriosis Drugs Sales Gonadotropins Releasing Hormone Agonists , by Region Kg (2018-2023)
  • Table 177. Endometriosis Drugs Sales Progestin , by Region Kg (2018-2023)
  • Table 178. Endometriosis Drugs Sales Non-Steroidal Anti-Inflammatory Drugs , by Region Kg (2018-2023)
  • Table 179. Endometriosis Drugs Sales Oral Contraceptive Pills , by Region Kg (2018-2023)
  • Table 180. South America Endometriosis Drugs Sales, by Country Kg (2018-2023)
  • Table 181. South America Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 182. South America Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 183. South America Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 184. South America Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 185. South America Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 186. Brazil Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 187. Brazil Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 188. Brazil Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 189. Brazil Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 190. Brazil Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 191. Argentina Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 192. Argentina Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 193. Argentina Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 194. Argentina Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 195. Argentina Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 196. Rest of South America Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 197. Rest of South America Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 198. Rest of South America Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 199. Rest of South America Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 200. Rest of South America Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 201. Asia Pacific Endometriosis Drugs Sales, by Country Kg (2018-2023)
  • Table 202. Asia Pacific Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 203. Asia Pacific Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 204. Asia Pacific Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 205. Asia Pacific Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 206. Asia Pacific Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 207. China Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 208. China Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 209. China Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 210. China Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 211. China Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 212. Japan Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 213. Japan Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 214. Japan Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 215. Japan Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 216. Japan Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 217. India Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 218. India Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 219. India Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 220. India Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 221. India Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 222. South Korea Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 223. South Korea Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 224. South Korea Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 225. South Korea Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 226. South Korea Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 227. Taiwan Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 228. Taiwan Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 229. Taiwan Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 230. Taiwan Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 231. Taiwan Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 232. Australia Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 233. Australia Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 234. Australia Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 235. Australia Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 236. Australia Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 237. Rest of Asia-Pacific Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 238. Rest of Asia-Pacific Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 239. Rest of Asia-Pacific Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 240. Rest of Asia-Pacific Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 241. Rest of Asia-Pacific Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 242. Europe Endometriosis Drugs Sales, by Country Kg (2018-2023)
  • Table 243. Europe Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 244. Europe Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 245. Europe Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 246. Europe Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 247. Europe Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 248. Germany Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 249. Germany Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 250. Germany Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 251. Germany Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 252. Germany Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 253. France Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 254. France Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 255. France Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 256. France Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 257. France Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 258. Italy Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 259. Italy Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 260. Italy Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 261. Italy Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 262. Italy Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 263. United Kingdom Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 264. United Kingdom Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 265. United Kingdom Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 266. United Kingdom Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 267. United Kingdom Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 268. Netherlands Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 269. Netherlands Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 270. Netherlands Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 271. Netherlands Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 272. Netherlands Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 273. Rest of Europe Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 274. Rest of Europe Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 275. Rest of Europe Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 276. Rest of Europe Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 277. Rest of Europe Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 278. MEA Endometriosis Drugs Sales, by Country Kg (2018-2023)
  • Table 279. MEA Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 280. MEA Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 281. MEA Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 282. MEA Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 283. MEA Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 284. Middle East Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 285. Middle East Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 286. Middle East Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 287. Middle East Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 288. Middle East Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 289. Africa Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 290. Africa Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 291. Africa Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 292. Africa Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 293. Africa Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 294. North America Endometriosis Drugs Sales, by Country Kg (2018-2023)
  • Table 295. North America Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 296. North America Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 297. North America Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 298. North America Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 299. North America Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 300. United States Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 301. United States Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 302. United States Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 303. United States Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 304. United States Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 305. Canada Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 306. Canada Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 307. Canada Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 308. Canada Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 309. Canada Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 310. Mexico Endometriosis Drugs Sales, by Application Kg (2018-2023)
  • Table 311. Mexico Endometriosis Drugs Sales, by Route of Administration Kg (2018-2023)
  • Table 312. Mexico Endometriosis Drugs Sales, by Therapy Type Kg (2018-2023)
  • Table 313. Mexico Endometriosis Drugs Sales, by Age Group Kg (2018-2023)
  • Table 314. Mexico Endometriosis Drugs Sales, by Drug Class Kg (2018-2023)
  • Table 315. Company Basic Information, Sales Area and Its Competitors
  • Table 316. Company Basic Information, Sales Area and Its Competitors
  • Table 317. Company Basic Information, Sales Area and Its Competitors
  • Table 318. Company Basic Information, Sales Area and Its Competitors
  • Table 319. Company Basic Information, Sales Area and Its Competitors
  • Table 320. Company Basic Information, Sales Area and Its Competitors
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Company Basic Information, Sales Area and Its Competitors
  • Table 324. Company Basic Information, Sales Area and Its Competitors
  • Table 325. Endometriosis Drugs: by Application(USD Million)
  • Table 326. Endometriosis Drugs Hospitals , by Region USD Million (2025-2030)
  • Table 327. Endometriosis Drugs Clinics , by Region USD Million (2025-2030)
  • Table 328. Endometriosis Drugs Research Institutes , by Region USD Million (2025-2030)
  • Table 329. Endometriosis Drugs Others , by Region USD Million (2025-2030)
  • Table 330. Endometriosis Drugs: by Route of Administration(USD Million)
  • Table 331. Endometriosis Drugs Oral , by Region USD Million (2025-2030)
  • Table 332. Endometriosis Drugs Nasal Spray , by Region USD Million (2025-2030)
  • Table 333. Endometriosis Drugs Intrauterine Systems , by Region USD Million (2025-2030)
  • Table 334. Endometriosis Drugs Parenteral , by Region USD Million (2025-2030)
  • Table 335. Endometriosis Drugs: by Therapy Type(USD Million)
  • Table 336. Endometriosis Drugs Pain Management , by Region USD Million (2025-2030)
  • Table 337. Endometriosis Drugs Hormonal Therapy , by Region USD Million (2025-2030)
  • Table 338. Endometriosis Drugs: by Age Group(USD Million)
  • Table 339. Endometriosis Drugs Child , by Region USD Million (2025-2030)
  • Table 340. Endometriosis Drugs Adult , by Region USD Million (2025-2030)
  • Table 341. Endometriosis Drugs Senior , by Region USD Million (2025-2030)
  • Table 342. Endometriosis Drugs: by Drug Class(USD Million)
  • Table 343. Endometriosis Drugs Gonadotropins Releasing Hormone Agonists , by Region USD Million (2025-2030)
  • Table 344. Endometriosis Drugs Progestin , by Region USD Million (2025-2030)
  • Table 345. Endometriosis Drugs Non-Steroidal Anti-Inflammatory Drugs , by Region USD Million (2025-2030)
  • Table 346. Endometriosis Drugs Oral Contraceptive Pills , by Region USD Million (2025-2030)
  • Table 347. South America Endometriosis Drugs, by Country USD Million (2025-2030)
  • Table 348. South America Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 349. South America Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 350. South America Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 351. South America Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 352. South America Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 353. Brazil Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 354. Brazil Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 355. Brazil Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 356. Brazil Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 357. Brazil Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 358. Argentina Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 359. Argentina Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 360. Argentina Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 361. Argentina Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 362. Argentina Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 363. Rest of South America Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 364. Rest of South America Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 365. Rest of South America Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 366. Rest of South America Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 367. Rest of South America Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 368. Asia Pacific Endometriosis Drugs, by Country USD Million (2025-2030)
  • Table 369. Asia Pacific Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 370. Asia Pacific Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 371. Asia Pacific Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 372. Asia Pacific Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 373. Asia Pacific Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 374. China Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 375. China Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 376. China Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 377. China Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 378. China Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 379. Japan Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 380. Japan Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 381. Japan Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 382. Japan Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 383. Japan Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 384. India Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 385. India Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 386. India Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 387. India Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 388. India Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 389. South Korea Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 390. South Korea Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 391. South Korea Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 392. South Korea Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 393. South Korea Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 394. Taiwan Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 395. Taiwan Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 396. Taiwan Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 397. Taiwan Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 398. Taiwan Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 399. Australia Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 400. Australia Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 401. Australia Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 402. Australia Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 403. Australia Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 404. Rest of Asia-Pacific Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 405. Rest of Asia-Pacific Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 406. Rest of Asia-Pacific Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 407. Rest of Asia-Pacific Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 408. Rest of Asia-Pacific Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 409. Europe Endometriosis Drugs, by Country USD Million (2025-2030)
  • Table 410. Europe Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 411. Europe Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 412. Europe Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 413. Europe Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 414. Europe Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 415. Germany Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 416. Germany Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 417. Germany Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 418. Germany Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 419. Germany Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 420. France Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 421. France Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 422. France Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 423. France Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 424. France Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 425. Italy Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 426. Italy Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 427. Italy Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 428. Italy Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 429. Italy Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 430. United Kingdom Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 431. United Kingdom Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 432. United Kingdom Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 433. United Kingdom Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 434. United Kingdom Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 435. Netherlands Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 436. Netherlands Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 437. Netherlands Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 438. Netherlands Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 439. Netherlands Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 440. Rest of Europe Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 441. Rest of Europe Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 442. Rest of Europe Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 443. Rest of Europe Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 444. Rest of Europe Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 445. MEA Endometriosis Drugs, by Country USD Million (2025-2030)
  • Table 446. MEA Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 447. MEA Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 448. MEA Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 449. MEA Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 450. MEA Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 451. Middle East Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 452. Middle East Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 453. Middle East Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 454. Middle East Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 455. Middle East Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 456. Africa Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 457. Africa Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 458. Africa Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 459. Africa Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 460. Africa Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 461. North America Endometriosis Drugs, by Country USD Million (2025-2030)
  • Table 462. North America Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 463. North America Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 464. North America Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 465. North America Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 466. North America Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 467. United States Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 468. United States Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 469. United States Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 470. United States Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 471. United States Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 472. Canada Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 473. Canada Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 474. Canada Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 475. Canada Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 476. Canada Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 477. Mexico Endometriosis Drugs, by Application USD Million (2025-2030)
  • Table 478. Mexico Endometriosis Drugs, by Route of Administration USD Million (2025-2030)
  • Table 479. Mexico Endometriosis Drugs, by Therapy Type USD Million (2025-2030)
  • Table 480. Mexico Endometriosis Drugs, by Age Group USD Million (2025-2030)
  • Table 481. Mexico Endometriosis Drugs, by Drug Class USD Million (2025-2030)
  • Table 482. Endometriosis Drugs Sales: by Application(Kg)
  • Table 483. Endometriosis Drugs Sales Hospitals , by Region Kg (2025-2030)
  • Table 484. Endometriosis Drugs Sales Clinics , by Region Kg (2025-2030)
  • Table 485. Endometriosis Drugs Sales Research Institutes , by Region Kg (2025-2030)
  • Table 486. Endometriosis Drugs Sales Others , by Region Kg (2025-2030)
  • Table 487. Endometriosis Drugs Sales: by Route of Administration(Kg)
  • Table 488. Endometriosis Drugs Sales Oral , by Region Kg (2025-2030)
  • Table 489. Endometriosis Drugs Sales Nasal Spray , by Region Kg (2025-2030)
  • Table 490. Endometriosis Drugs Sales Intrauterine Systems , by Region Kg (2025-2030)
  • Table 491. Endometriosis Drugs Sales Parenteral , by Region Kg (2025-2030)
  • Table 492. Endometriosis Drugs Sales: by Therapy Type(Kg)
  • Table 493. Endometriosis Drugs Sales Pain Management , by Region Kg (2025-2030)
  • Table 494. Endometriosis Drugs Sales Hormonal Therapy , by Region Kg (2025-2030)
  • Table 495. Endometriosis Drugs Sales: by Age Group(Kg)
  • Table 496. Endometriosis Drugs Sales Child , by Region Kg (2025-2030)
  • Table 497. Endometriosis Drugs Sales Adult , by Region Kg (2025-2030)
  • Table 498. Endometriosis Drugs Sales Senior , by Region Kg (2025-2030)
  • Table 499. Endometriosis Drugs Sales: by Drug Class(Kg)
  • Table 500. Endometriosis Drugs Sales Gonadotropins Releasing Hormone Agonists , by Region Kg (2025-2030)
  • Table 501. Endometriosis Drugs Sales Progestin , by Region Kg (2025-2030)
  • Table 502. Endometriosis Drugs Sales Non-Steroidal Anti-Inflammatory Drugs , by Region Kg (2025-2030)
  • Table 503. Endometriosis Drugs Sales Oral Contraceptive Pills , by Region Kg (2025-2030)
  • Table 504. South America Endometriosis Drugs Sales, by Country Kg (2025-2030)
  • Table 505. South America Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 506. South America Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 507. South America Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 508. South America Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 509. South America Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 510. Brazil Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 511. Brazil Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 512. Brazil Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 513. Brazil Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 514. Brazil Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 515. Argentina Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 516. Argentina Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 517. Argentina Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 518. Argentina Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 519. Argentina Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 520. Rest of South America Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 521. Rest of South America Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 522. Rest of South America Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 523. Rest of South America Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 524. Rest of South America Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 525. Asia Pacific Endometriosis Drugs Sales, by Country Kg (2025-2030)
  • Table 526. Asia Pacific Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 527. Asia Pacific Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 528. Asia Pacific Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 529. Asia Pacific Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 530. Asia Pacific Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 531. China Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 532. China Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 533. China Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 534. China Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 535. China Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 536. Japan Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 537. Japan Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 538. Japan Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 539. Japan Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 540. Japan Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 541. India Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 542. India Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 543. India Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 544. India Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 545. India Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 546. South Korea Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 547. South Korea Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 548. South Korea Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 549. South Korea Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 550. South Korea Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 551. Taiwan Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 552. Taiwan Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 553. Taiwan Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 554. Taiwan Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 555. Taiwan Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 556. Australia Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 557. Australia Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 558. Australia Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 559. Australia Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 560. Australia Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 561. Rest of Asia-Pacific Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 562. Rest of Asia-Pacific Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 563. Rest of Asia-Pacific Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 564. Rest of Asia-Pacific Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 565. Rest of Asia-Pacific Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 566. Europe Endometriosis Drugs Sales, by Country Kg (2025-2030)
  • Table 567. Europe Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 568. Europe Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 569. Europe Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 570. Europe Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 571. Europe Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 572. Germany Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 573. Germany Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 574. Germany Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 575. Germany Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 576. Germany Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 577. France Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 578. France Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 579. France Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 580. France Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 581. France Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 582. Italy Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 583. Italy Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 584. Italy Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 585. Italy Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 586. Italy Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 587. United Kingdom Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 588. United Kingdom Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 589. United Kingdom Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 590. United Kingdom Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 591. United Kingdom Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 592. Netherlands Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 593. Netherlands Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 594. Netherlands Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 595. Netherlands Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 596. Netherlands Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 597. Rest of Europe Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 598. Rest of Europe Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 599. Rest of Europe Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 600. Rest of Europe Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 601. Rest of Europe Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 602. MEA Endometriosis Drugs Sales, by Country Kg (2025-2030)
  • Table 603. MEA Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 604. MEA Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 605. MEA Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 606. MEA Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 607. MEA Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 608. Middle East Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 609. Middle East Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 610. Middle East Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 611. Middle East Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 612. Middle East Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 613. Africa Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 614. Africa Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 615. Africa Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 616. Africa Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 617. Africa Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 618. North America Endometriosis Drugs Sales, by Country Kg (2025-2030)
  • Table 619. North America Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 620. North America Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 621. North America Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 622. North America Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 623. North America Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 624. United States Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 625. United States Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 626. United States Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 627. United States Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 628. United States Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 629. Canada Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 630. Canada Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 631. Canada Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 632. Canada Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 633. Canada Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 634. Mexico Endometriosis Drugs Sales, by Application Kg (2025-2030)
  • Table 635. Mexico Endometriosis Drugs Sales, by Route of Administration Kg (2025-2030)
  • Table 636. Mexico Endometriosis Drugs Sales, by Therapy Type Kg (2025-2030)
  • Table 637. Mexico Endometriosis Drugs Sales, by Age Group Kg (2025-2030)
  • Table 638. Mexico Endometriosis Drugs Sales, by Drug Class Kg (2025-2030)
  • Table 639. Research Programs/Design for This Report
  • Table 640. Key Data Information from Secondary Sources
  • Table 641. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Endometriosis Drugs: by Application USD Million (2018-2023)
  • Figure 5. Global Endometriosis Drugs: by Route of Administration USD Million (2018-2023)
  • Figure 6. Global Endometriosis Drugs: by Therapy Type USD Million (2018-2023)
  • Figure 7. Global Endometriosis Drugs: by Age Group USD Million (2018-2023)
  • Figure 8. Global Endometriosis Drugs: by Drug Class USD Million (2018-2023)
  • Figure 9. South America Endometriosis Drugs Share (%), by Country
  • Figure 10. Asia Pacific Endometriosis Drugs Share (%), by Country
  • Figure 11. Europe Endometriosis Drugs Share (%), by Country
  • Figure 12. MEA Endometriosis Drugs Share (%), by Country
  • Figure 13. North America Endometriosis Drugs Share (%), by Country
  • Figure 14. Global Endometriosis Drugs: by Application Kg (2018-2023)
  • Figure 15. Global Endometriosis Drugs: by Route of Administration Kg (2018-2023)
  • Figure 16. Global Endometriosis Drugs: by Therapy Type Kg (2018-2023)
  • Figure 17. Global Endometriosis Drugs: by Age Group Kg (2018-2023)
  • Figure 18. Global Endometriosis Drugs: by Drug Class Kg (2018-2023)
  • Figure 19. South America Endometriosis Drugs Share (%), by Country
  • Figure 20. Asia Pacific Endometriosis Drugs Share (%), by Country
  • Figure 21. Europe Endometriosis Drugs Share (%), by Country
  • Figure 22. MEA Endometriosis Drugs Share (%), by Country
  • Figure 23. North America Endometriosis Drugs Share (%), by Country
  • Figure 24. Global Endometriosis Drugs share by Players 2023 (%)
  • Figure 25. Global Endometriosis Drugs share by Players (Top 3) 2023(%)
  • Figure 26. Global Endometriosis Drugs share by Players (Top 5) 2023(%)
  • Figure 27. BCG Matrix for key Companies
  • Figure 28. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 29. AbbVie (United States) Revenue: by Geography 2023
  • Figure 30. Astellas Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 31. Astellas Pharma (Japan) Revenue: by Geography 2023
  • Figure 32. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. AstraZeneca plc (United Kingdom) Revenue: by Geography 2023
  • Figure 34. Debiopharm Group (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. Debiopharm Group (Switzerland) Revenue: by Geography 2023
  • Figure 36. Evotec AG (Germany) Revenue, Net Income and Gross profit
  • Figure 37. Evotec AG (Germany) Revenue: by Geography 2023
  • Figure 38. Kissei Pharmaceutical (Japan) Revenue, Net Income and Gross profit
  • Figure 39. Kissei Pharmaceutical (Japan) Revenue: by Geography 2023
  • Figure 40. Neurocrine Biosciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 41. Neurocrine Biosciences, Inc. (United States) Revenue: by Geography 2023
  • Figure 42. ObsEva (Switzerland) Revenue, Net Income and Gross profit
  • Figure 43. ObsEva (Switzerland) Revenue: by Geography 2023
  • Figure 44. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 45. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 46. Repros Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 47. Repros Therapeutics Inc. (United States) Revenue: by Geography 2023
  • Figure 48. Global Endometriosis Drugs: by Application USD Million (2025-2030)
  • Figure 49. Global Endometriosis Drugs: by Route of Administration USD Million (2025-2030)
  • Figure 50. Global Endometriosis Drugs: by Therapy Type USD Million (2025-2030)
  • Figure 51. Global Endometriosis Drugs: by Age Group USD Million (2025-2030)
  • Figure 52. Global Endometriosis Drugs: by Drug Class USD Million (2025-2030)
  • Figure 53. South America Endometriosis Drugs Share (%), by Country
  • Figure 54. Asia Pacific Endometriosis Drugs Share (%), by Country
  • Figure 55. Europe Endometriosis Drugs Share (%), by Country
  • Figure 56. MEA Endometriosis Drugs Share (%), by Country
  • Figure 57. North America Endometriosis Drugs Share (%), by Country
  • Figure 58. Global Endometriosis Drugs: by Application Kg (2025-2030)
  • Figure 59. Global Endometriosis Drugs: by Route of Administration Kg (2025-2030)
  • Figure 60. Global Endometriosis Drugs: by Therapy Type Kg (2025-2030)
  • Figure 61. Global Endometriosis Drugs: by Age Group Kg (2025-2030)
  • Figure 62. Global Endometriosis Drugs: by Drug Class Kg (2025-2030)
  • Figure 63. South America Endometriosis Drugs Share (%), by Country
  • Figure 64. Asia Pacific Endometriosis Drugs Share (%), by Country
  • Figure 65. Europe Endometriosis Drugs Share (%), by Country
  • Figure 66. MEA Endometriosis Drugs Share (%), by Country
  • Figure 67. North America Endometriosis Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AbbVie (United States)
  • Astellas Pharma (Japan)
  • AstraZeneca plc (United Kingdom)
  • Debiopharm Group (Switzerland)
  • Evotec AG (Germany)
  • Kissei Pharmaceutical (Japan)
  • Neurocrine Biosciences, Inc. (United States)
  • ObsEva (Switzerland)
  • Pfizer Inc. (United States)
  • Repros Therapeutics Inc. (United States)
Additional players considered in the study are as follows:
Roivant Sciences GmbH (Switzerland) , Takeda Pharmaceutical Company Limited (Japan) , ValiRx (United Kingdom)
Select User Access Type

Key Highlights of Report


Jan 2024 243 Pages 88 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global (United States, European Union and China) Endometriosis Drugs Quantitative research analysis
Global (United States, European Union and China) Endometriosis Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as AbbVie (United States), Astellas Pharma (Japan), AstraZeneca plc (United Kingdom), Debiopharm Group (Switzerland), Evotec AG (Germany), Kissei Pharmaceutical (Japan), Neurocrine Biosciences, Inc. (United States), ObsEva (Switzerland), Pfizer Inc. (United States) and Repros Therapeutics Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"increased Adoption of Oral Contraceptive Pill" is seen as one of major influencing trends for Endometriosis Drugs Market during projected period 2023-2030.
The Endometriosis Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global (United States, European Union and China) Endometriosis Drugs Report?

Have a Query? Click Here

Other Related Reports

Azacitidine Drug Comprehensive Study by Type (Acute myeloid leukemia (AML), Myelodysplastic syndrome (MDS)), Application (Refractory anemia (RA), Refractory anemia with excess blasts (RAEB), Chronic ...
$ 3750
Angina Pectoris Drugs Comprehensive Study by Type (Nitrates, Non-Steroidal Anti-Inflammatory Drugs, Anti-Platelet Drugs, Beta Blockers, Statins, Calcium Antagonists, Angiotensin-Converting Enzyme (Ac...
$ 3750
Polymixin Comprehensive Study by Type (Polymyxin B, Polymyxin E), Application (Humans, Veterinary {Pigs, Poultry, Cattle, Sheep, Goats, Rabbits, and Others}), Administration Route (Oral, Injection) P...
$ 3500
Tiotropium bromide Comprehensive Study by Type (Inhalation Powder, Inhalation Spray), Application (Hospital, Clinics), End Users (Asthma Patients, Chronic Obstructive Pulmonary Disease (COPD) Patient...
$ 3500
Retail Drug Comprehensive Study by Application (Hospital, Clinic, Hoem Use), Type (Generic Drug, OTC Drug, Others), Drug Type (Cough, Cold, and Flu Products, Analgesics, Vitamins, Mineral, and Suppl...
$ 3650
Miconazole Nitrate Comprehensive Study by Type (Oral, Cream), Application (Vaginal Treatment, External Skin Treatment, Oral Treatment), Ingredient (BHA (Beta Hydroxy Acid), BHT (Butylated Hydroxytolu...
$ 3450